Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Dendritic cells and the control of immunity

Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,244 · see citing works

Angiogenesis in cancer and other diseases

Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615 · see citing works

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · see citing works

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360 · see citing works

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091 · see citing works

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804 · see citing works

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589 · see citing works

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265 · see citing works

Induction of tolerance by IL-10-treated dendritic cells

Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,245 · see citing works

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

Mayordomo, J. I., Zorina, T. D., Storkus, W. J., Zitvogel, L., Celluzzi, C. M., Falo, L. D., Melief, C. J. M., Ildstad, S. T., Kast, W. M., DeLeo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,075 · see citing works

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.1.87 · Cited by 828 · see citing works

Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4

Chang, C.-C., Ciubotariu, R., Manavalan, J. S., Yuan, J., Colovai, A. I., Piazza, F., Lederman, S. M., Colonna, M., Cortesini, R., Dalla‐Favera, R., et al. (2002) · Nature Immunology · doi:10.1038/ni760 · Cited by 803 · see citing works

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

Zou, W., Machelon, V., L’Herminé, A. C., Borvak, J., Mercier‐Nomé, F., Isaeva, T., Wei, S., Krzysiek, R., Durand–Gasselin, I., Gordon, A. N., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653 · see citing works

Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor

Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590 · see citing works

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.

Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., & Senger, D. R. (1993) · PubMed Central · Cited by 558 · see citing works

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.

Llorente, L., Zou, W., Lévy, Y., Richaud‐Patín, Y., Wijdenes, J., Alcocer-Varela, J. C., Morel-Fourrier, B., Brouet, J. C., Alarcón-Segovia, D., Galanaud, P., et al. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.839 · Cited by 540 · see citing works

Role of Vascular Endothelial Growth Factor in Ovarian Cancer

Mesiano, S. A., Ferrara, N., & Jaffe, R. B. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392 · see citing works

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis

高橋, 敦. (1994) · Medical Entomology and Zoology · doi:10.11501/3101325 · Cited by 355 · see citing works

B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis

Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 326 · see citing works

Dendritic cells: On the move from bench to bedside

Nestle, F. O., Banchereau, J., & Hart, D. N. J. (2001) · Nature Medicine · doi:10.1038/89863 · Cited by 288 · see citing works

Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction

Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 288 · see citing works

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K.-I., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., & Terada, M. (1994) · PubMed · Cited by 277 · see citing works

B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function

Tamura, H., Dong, H., Zhu, G., Sica, G., Flies, D. B., Tamada, K., & Chen, L. (2001) · Blood · doi:10.1182/blood.v97.6.1809 · Cited by 218 · see citing works

Quantitative analysis of vascular endothelial growth factor in primary breast cancer

Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., Taniguchi, T., & Tominaga, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960315)77:6 · Cited by 192 · see citing works

Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis

Dong, H., Strome, S. E., Matteson, E. L., Moder, K. G., Flies, D. B., Zhu, G., Tamura, H., Driscoll, C. L. W., & Chen, L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16015 · Cited by 188 · see citing works

Identification of an IL-10-Producing HLA-DR-Negative Monocyte Subset in the Malignant Ascites of Patients with Ovarian Carcinoma That Inhibits Cytokine Protein Expression and Proliferation of Autologous T Cells

Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D., & Freedman, R. S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.11.6251 · Cited by 174 · see citing works

Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.

Strome, S. E., Voss, S. G., Wilcox, R. A., Wakefield, T. L., Tamada, K., Flies, D. B., Chapoval, A. I., Lu, J., Kasperbauer, J. L., Padley, D. J., et al. (2002) · PubMed · Cited by 153 · see citing works

Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by β-Chemokines Rather Than IL-12

Zou, W., Borvak, J., Marches, F., Wei, S., Galanaud, P., Émilie, D., & Curiel, T. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4388 · Cited by 137 · see citing works

Interleukin-12: Basic Principles and Clinical Applications

Trinchieri, G., & Scott, P. (1999) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-09709-0_4 · Cited by 111 · see citing works

T cells and tumours

Pardoll, D. M. (2001) · Nature · doi:10.1038/35082676 · Cited by 87 · see citing works

IL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivoa

Zitvogel, L., Couderc, B. C., Mayordomo, J. I., Robbins, P. D., Lotze, M. T., & Storkus, W. J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb52678.x · Cited by 87 · see citing works

Tamura, H. et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97, 1809-1816

Tamada, K., Hd, D., Gf, Z., Sica, G., Tamura, H., Flies, D. B., & Lp, C. (2001) · Cited by 39 · see citing works

Quantification of cytokine gene expression by competitive PCR using a colorimetric assay.

Zou, W., Durand–Gasselin, I., Dulioust, A., Maillot, M., Galanaud, P., & Émilie, D. (1995) · PubMed · Cited by 37 · see citing works

T cells and tumors

Maas, R. A., Dullens, H. F. J., & Otter, W. D. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90141-s · Cited by 17 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

The JAK/STAT signaling pathway: from bench to clinic

Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633 · see citing works

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works

The B7 family revisited

Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · see citing works

Crosstalk between cancer‐associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290 · see citing works

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,185 · see citing works

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189 · see citing works

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works

Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms

Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000 · see citing works

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,973 · see citing works

The diverse functions of the PD1 inhibitory pathway

Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 1,977 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,699 · see citing works

Inhibitory B7-family molecules in the tumour microenvironment

Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,432 · see citing works

Immune checkpoint signaling and cancer immunotherapy

He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,383 · see citing works

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 ⁺ T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · see citing works

PD-1 and PD-1 ligands: from discovery to clinical application

Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · see citing works

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

Chen, L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1349 · Cited by 1,257 · see citing works

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · see citing works

Overcoming T cell exhaustion in infection and cancer

Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,177 · see citing works

Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology

Semenza, G. L. (2013) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,159 · see citing works

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Rosenwald, A., Wright, G. W., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haïoun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,095 · see citing works

Radiotherapy and immunotherapy: a beneficial liaison?

Weichselbaum, R. R., Liang, H. L., Deng, L., & Fu, Y. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,073 · see citing works

Mechanisms Controlling PD-L1 Expression in Cancer

Cha, J., Chan, L.-C., Li, C., Hsu, J. L., & Hung, M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,054 · see citing works

Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11

Lang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0338 · Cited by 1,065 · see citing works

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., Rizvi, S. M., Qin, A., Waninger, J. J., Lang, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1131-x · Cited by 1,010 · see citing works

Cancer nanomedicine for combination cancer immunotherapy

Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 946 · see citing works

ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis

Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933 · see citing works

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 915 · see citing works

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 897 · see citing works

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works

Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up

Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869 · see citing works

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments

Kryczek, I., Banerjee, M., Cheng, P. J., Vatan, L., Szeliga, W., Wei, S., Huang, E. H., Finlayson, E. V. A., Simeone, D. M., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 814 · see citing works

Regulatory mechanisms of PD-1/PD-L1 in cancers

Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 850 · see citing works

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · see citing works

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

Sharma, M. D., Baban, B., Chandler, P., Hou, D., Singh, N., Yagita∥, H., Azuma, M., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31911 · Cited by 791 · see citing works

The role of myeloid cells in cancer therapies

Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788 · see citing works

PD-L1 expression in human cancers and its association with clinical outcomes

Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787 · see citing works

A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells

Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767 · see citing works

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · see citing works

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · see citing works

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 743 · see citing works

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor

Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · see citing works

The PD-1–PD-L pathway in immunological tolerance

Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 720 · see citing works

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

Konishi, J. S., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka‐Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678 · see citing works

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 661 · see citing works

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

Blank, C. U., Gajewski, T. F., & Mackensen, A. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 634 · see citing works

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy

Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629 · see citing works

Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Nguyen, L. T., & Ohashi, P. S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3790 · Cited by 621 · see citing works

The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

Ghebeh, H., Mohammed, S. F., Al-Omair, A., Qattan, A. T., Lehé, C. L., Al-Qudaihi, G., Elkum, N. B., Alshabanah, M., Amer, S. M. B., Tulbah, A. M., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612 · see citing works

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

Li, C., Lim, S., Chung, E. M., Kim, Y., Park, A. H., Yao, J., Cha, J., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 611 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

Wang, C., Thudium, K. B., Han, M., Wang, X., Huang, H., Feingersh, D., Garcia, C., Wu, Y. M., Kuhné, M. R., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 603 · see citing works

Deciphering and Reversing Tumor Immune Suppression

Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 600 · see citing works

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96113 · Cited by 580 · see citing works

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway

Liu, J., Hamrouni, A., Wołowiec, D., Coiteux, V., Kuliczkowski, K., Hétuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580 · see citing works

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

Huang, A. C. C., & Zappasodi, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01141-1 · Cited by 573 · see citing works

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J. F., Heslop, H., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 568 · see citing works

cGAS is essential for the antitumor effect of immune checkpoint blockade

Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563 · see citing works

PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553 · see citing works

Tregs and rethinking cancer immunotherapy

Curiel, T. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31202 · Cited by 545 · see citing works

Immune checkpoints and their inhibition in cancer and infectious diseases

Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541 · see citing works

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 543 · see citing works

Revisiting the PD-1 pathway

Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 539 · see citing works

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade

Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533 · see citing works

Application of PD-1 Blockade in Cancer Immunotherapy

Wu, X., Gu, Z., Yang, C., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 524 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 529 · see citing works

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond

Ai, L., Xu, A., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 531 · see citing works

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 519 · see citing works

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

Yang, Y., Li, C., Chan, L.-C., Wei, Y., Hsu, J.-M., Xia, W., Cha, J., Hou, J., Hsu, J. L., Sun, L., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0060-4 · Cited by 515 · see citing works

Cancer Immunotherapy by Dendritic Cells

Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 505 · see citing works

PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 508 · see citing works

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

Blank, C. U., & Mackensen, A. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0272-1 · Cited by 502 · see citing works

Pembrolizumab (Keytruda)

Kwok, G. W., Yau, T. C. C., Chiu, J. W. Y., Tse, E., & Kwong, Y. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1199310 · Cited by 509 · see citing works

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells

Obermajer, N., Muthuswamy, R., Lesnock, J. L., Edwards, R. P., & Kaliński, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 499 · see citing works

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496 · see citing works

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 492 · see citing works

Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells

Duluc, D., Delneste, Y., Tan, F., Moles, M., Grimaud, L., Lenoir, J., Preisser, L., Anegón, I., Catala, L., Ifrah, N., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072587 · Cited by 490 · see citing works

VISTA Regulates the Development of Protective Antitumor Immunity

Mercier, I. L., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P. A., Noelle, R. J., & Wang, L. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 490 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 490 · see citing works

The parallel lives of angiogenesis and immunosuppression: cancer and other tales

Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481 · see citing works

Immune Checkpoint Inhibitors: Basics and Challenges

Li, B., Chan, H. L., & Chen, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170804143706 · Cited by 473 · see citing works

A Major Lung CD103 (αE)-β7 Integrin-Positive Epithelial Dendritic Cell Population Expressing Langerin and Tight Junction Proteins

Sung, S. J., Fu, S. M., Rose, C. E., Gaskin, F., Ju, S., & Beaty, S. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2161 · Cited by 476 · see citing works

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W. P., Wang, J., Wang, X., & Fu, Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 477 · see citing works

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473 · see citing works

The Intersection between Tumor Angiogenesis and Immune Suppression

Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 473 · see citing works

Induction of IL-17+ T Cell Trafficking and Development by IFN-γ: Mechanism and Pathological Relevance in Psoriasis

Kryczek, I., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Aphale, A., Vatan, L., Szeliga, W., Wang, Y., Liu, Y., Welling, T. H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4733 · Cited by 464 · see citing works

Nanoparticle-Based Immunotherapy for Cancer

Shao, K., Singha, S., Clemente‐Casares, X., Tsai, S. J., Yang, Y., & Santamaría, P. (2014) · ACS Nano · doi:10.1021/nn5062029 · Cited by 472 · see citing works

Classification of current anticancer immunotherapies

Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 471 · see citing works

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629600 · Cited by 469 · see citing works

Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma

Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459 · see citing works

Effects of B7-H1 molecule blockade on tumor-infiltrating dendritic cell-mediated T-cell function

Chen, Y., Xiaohua, L., Ruofan, H., & Zhou, X. (2009) · 癌症：英文版

Soluble B7-H1: Differences in production between dendritic cells and T cells

Frigola, X., Inman, B. A., Krco, C. J., Liu, X., Harrington, S. M., Bulur, P. A., Dietz, A. B., Dong, H., & Kwon, E. D. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.11.001 · Cited by 138 · see citing works

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer

Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. C., & Yang, R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.030 · Cited by 102 · see citing works

Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer

Krempski, J. W., Karyampudi, L., Behrens, M. D., Erskine, C. L., Hartmann, L. C., Dong, H., Goode, E. L., Kalli, K. R., & Knutson, K. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100274 · Cited by 255 · see citing works

B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction

Chen, L., Azuma, T., Yu, W., Xu, Z., Luo, L., & Chen, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722043115 · Cited by 30 · see citing works